M. Bian1, R. Bissonnette2, T. Luger3, D. Thaci4, D. Toth5, S. Xia6, R. Mazur7, M. Milutinovic7, C. Leonardi8
Achieving a low absolute Psoriasis Area and Severity Index (PASI) score is a desired clinical outcome and an important measure of treatment efficacy. Here, we assess the sustainability of secukinumab efficacy in moderate to severe psoriasis patients treated for up to 4 years.
In the core SCULPTURE study, PASI75 responders at Week 12 were randomised to a double-blind maintenance treatment of subcutaneous secukinumab 300 mg or 150 mg, administered either at a 4-week fixed-interval or in a retreatment-as-needed regimen. Patients who completed 52 weeks of treatment continued into an extension study and received the same blinded maintenance treatment regimen up to 3 Years. In the fourth year, the study was open-label, and treatment was mainly self-administered by patients with site visits occurring every 12–16 weeks. Herein, we report absolute PASI≤1/≤2/≤3/≤5 responses at Week 52 and Week 208, focusing on the 300 mg fixedinterval treatment arm in line with the approved dosing regimen.
Overall, 78% of patients completed secukinumab treatment through to Wk 208. Secukinumab 300 mg demonstrated sustained efficacy over 4 years in patients with moderate to severe psoriasis. Absolute PASI ≤1/≤2/≤3/≤5 at Wk 52 were well-sustained to Year 4 (refer to table in e-poster). Treatment adherence in Year 4, when patients were mainly self-administering therapy, was 99.5%. The favourable safety profile of secukinumab was also maintained to Year 4, with no cumulative or unexpected safety signals identified.
Secukinumab 300 mg demonstrates sustained efficacy up to 4 years, as seen by low absolute PASI scores and patients achieving significant levels of skin clearance, with a favourable safety profile.